Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
2.
J Biol Chem ; 288(38): 27200-27207, 2013 Sep 20.
Artículo en Inglés | MEDLINE | ID: mdl-23940028

RESUMEN

Streptozotocin (STZ) is widely used as diabetogenic agent in animal models for diabetic nephropathy (DN). However, it is also directly cytotoxic to kidneys, making it difficult to distinguish between DN-related and STZ-induced nephropathy. Therefore, an improved protocol to generate mice for DN studies, with a quick and robust achievement of the diabetic state, without direct kidney toxicity is required. To investigate the mechanism leading to STZ-induced nephropathy, kidney damage was induced with a high dose of STZ. This resulted in delayed gastric emptying, at least partially caused by impaired desacyl ghrelin clearance. STZ uptake in the kidneys is to a large extent mediated by the sodium/glucose cotransporters (Sglts) because the Sglt inhibitor phlorizin could reduce STZ uptake in the kidneys. Consequently, the direct toxic effects in the kidney and the gastric dilatation were resolved without interfering with the ß-cell toxicity. Furthermore, pancreatic STZ uptake was increased, hereby decreasing the threshold for ß-cell toxicity, allowing for single low non-nephrotoxic STZ doses (70 mg/kg). In conclusion, this study provides novel insights into the mechanism of STZ toxicity in kidneys and suggests a more efficient regime to induce DN with little or no toxic side effects.


Asunto(s)
Nefropatías Diabéticas/prevención & control , Células Secretoras de Insulina/metabolismo , Riñón/metabolismo , Florizina/farmacología , Transportador 1 de Sodio-Glucosa/antagonistas & inhibidores , Animales , Antibióticos Antineoplásicos/efectos adversos , Antibióticos Antineoplásicos/farmacocinética , Antibióticos Antineoplásicos/farmacología , Diabetes Mellitus Experimental/inducido químicamente , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/patología , Nefropatías Diabéticas/inducido químicamente , Nefropatías Diabéticas/metabolismo , Nefropatías Diabéticas/patología , Relación Dosis-Respuesta a Droga , Células Secretoras de Insulina/patología , Riñón/lesiones , Riñón/patología , Masculino , Ratones , Transportador 1 de Sodio-Glucosa/metabolismo , Estreptozocina/efectos adversos , Estreptozocina/farmacocinética , Estreptozocina/farmacología
4.
Eur J Cell Biol ; 96(5): 432-439, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28413120

RESUMEN

Proprotein Convertase 7 (PC7) is a Furin-like endoprotease that cleaves precursor proteins at basic amino acids. PC7 is concentrated in the trans-Golgi network (TGN) but it shuttles between the plasma membrane and the TGN depending on sequences in the cytoplasmic tail. A short region containing a three amino acids motif, P724-L725-C726, is essential and sufficient for internalization of PC7 but not for TGN localization, which requires the additional presence of the juxtamembrane region. In this study we have investigated the contribution of a cluster of basic amino acids and two reversibly palmitoylated cysteine residues to endocytic trafficking. Stable cell lines overexpressing chimeric proteins (CD25 and CD46) containing the cytoplasmic domain of PC7 in which the basic cluster alone or together with both palmitoylated cysteines are mutated showed enhanced surface expression as demonstrated by immunofluorescence experiments and surface biotinylation. The mutant proteins no longer recycled to the TGN in antibody uptake experiments and accumulated in an endosomal compartment. Recycling of wild type PC7 to the TGN is blocked by nocodazole, suggesting that PC7 shuttles to the TGN via late endosomes, similar to Furin. Unlike furin, however, PC7 was found to recycle to a region within the TGN, which is deficient in sialyltransferase, as shown by resialylation experiments. In conclusion, a novel motif, composed of a basic amino acid cluster and two palmitoylated cysteines are essential for TGN localization and endocytic trafficking.


Asunto(s)
Endocitosis/fisiología , Endosomas/metabolismo , Subtilisinas/metabolismo , Red trans-Golgi/metabolismo , Aminoácidos Básicos/metabolismo , Animales , Células Cultivadas , Cisteína/metabolismo , Lipoilación , Transporte de Proteínas/fisiología , Ratas
5.
PLoS One ; 10(8): e0135502, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26275221

RESUMEN

The Nestin-Cre driver mouse line has mild hypopituitarism, reduced body weight, a metabolic phenotype and reduced anxiety. Although several causes have been suggested, a comprehensive explanation is still lacking. In this study we examined the molecular mechanisms leading to this compound phenotype. Upon generation of the Nestin-Cre mice, the human growth hormone (hGH) minigene was inserted downstream of the Cre recombinase to ensure efficient transgene expression. As a result, hGH is expressed in the hypothalamus. This results in the auto/paracrine activation of the GH receptor as demonstrated by the increased phosphorylation of signal transducer and activator of transcription 5 (STAT5) and reduced expression of growth hormone releasing hormone (Ghrh). Low Ghrh levels cause hypopituitarism consistent with the observed mouse growth hormone (mGH) deficiency. mGH deficiency caused reduced activation of the GH receptor and hence reduced phosphorylation of STAT5 in the liver. This led to decreased levels of hepatic Igf-1 mRNA and consequently postnatal growth retardation. Furthermore, genes involved in lipid uptake and synthesis, such as CD36 and very low-density lipoprotein receptor were upregulated, resulting in liver steatosis. In conclusion, this study demonstrates the unexpected expression of hGH in the hypothalamus of Nestin-Cre mice which is able to activate both the GH receptor and the prolactin receptor. Increased hypothalamic GH receptor signaling explains the observed hypopituitarism, reduced growth and metabolic phenotype of Nestin-Cre mice. Activation of either receptor is consistent with reduced anxiety.


Asunto(s)
Hormona de Crecimiento Humana/metabolismo , Hipotálamo/metabolismo , Animales , Hormona Liberadora de Hormona del Crecimiento/metabolismo , Humanos , Factor I del Crecimiento Similar a la Insulina/metabolismo , Integrasas/metabolismo , Hígado/metabolismo , Masculino , Ratones , Ratones Transgénicos , Nestina/metabolismo , ARN Mensajero/genética , Receptores de LDL/metabolismo , Factor de Transcripción STAT5/metabolismo
6.
Biomed Res Int ; 2015: 148651, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26167473

RESUMEN

Proprotein convertases are subtilisin-like serine endoproteases that cleave and hence activate a variety of proproteins, including growth factors, receptors, metalloproteases, and extracellular matrix proteins. Therefore, it has been suggested that inhibition of the ubiquitously expressed proprotein convertase FURIN might be a good therapeutic strategy for several tumor types. Whether this is also the case for hepatocellular carcinoma (HCC) is currently not clear. In a mouse model for HCC expression of Furin was not altered in the tumors, while those of PC7, PC5/6, and PACE4 significantly decreased, at least at some time points. To investigate the impact of Furin inhibition on the development and progression of HCC in this model, Furin was genetically ablated in the liver. Furin inactivation resulted in an increased tumor mass after 5 weeks. This was not caused by decreased apoptosis, since no differences in the apoptosis index could be observed. However, it could at least partially be explained by increased hepatocyte proliferation at 5 weeks. The tumors of the Furin knockout mice were histologically similar to those in wild type mice. In conclusion, liver-specific Furin inhibition in HCC enhances the tumor formation and will not be a good therapeutic strategy for this tumor type.


Asunto(s)
Furina/antagonistas & inhibidores , Furina/metabolismo , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/metabolismo , Hígado/metabolismo , Animales , Apoptosis/genética , Biomarcadores de Tumor/análisis , Biomarcadores de Tumor/metabolismo , Femenino , Furina/genética , Hígado/patología , Neoplasias Hepáticas/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados
7.
PLoS One ; 9(10): e109598, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25333629

RESUMEN

Two knockout mouse models for the autism candidate gene Neurobeachin (Nbea) have been generated independently. Although both models have similar phenotypes, one striking difference is the dwarf phenotype observed in the heterozygous configuration of the GH240B model that is generated by the serendipitous insertion of a promoterless human growth hormone (hGH) genomic fragment in the Nbea gene. In order to elucidate this discrepancy, the dwarfism present in this Nbea mouse model was investigated in detail. The growth deficiency in Nbea+/- mice coincided with an increased percentage of fat mass and a decrease in bone mineral density. Low but detectable levels of hGH were detected in the pituitary and hypothalamus of Nbea+/- mice but not in liver, hippocampus nor in serum. As a consequence, several members of the mouse growth hormone (mGH) signaling cascade showed altered mRNA levels, including a reduction in growth hormone-releasing hormone mRNA in the hypothalamus. Moreover, somatotrope cells were less numerous in the pituitary of Nbea+/- mice and both contained and secreted significantly less mGH resulting in reduced levels of circulating insulin-like growth factor 1. These findings demonstrate that the random integration of the hGH transgene in this mouse model has not only inactivated Nbea but has also resulted in the tissue-specific expression of hGH causing a negative feedback loop, mGH hyposecretion and dwarfism.


Asunto(s)
Proteínas Portadoras/genética , Enanismo/genética , Haploinsuficiencia , Hormona de Crecimiento Humana/genética , Proteínas del Tejido Nervioso/genética , Proteínas Recombinantes/genética , Animales , Trastorno Autístico/genética , Trastorno Autístico/metabolismo , Proteínas Portadoras/metabolismo , Modelos Animales de Enfermedad , Enanismo/metabolismo , Expresión Génica , Hormona de Crecimiento Humana/metabolismo , Humanos , Hipotálamo/metabolismo , Proteínas de la Membrana , Ratones , Ratones Noqueados , Proteínas del Tejido Nervioso/metabolismo , Fenotipo , Hipófisis/metabolismo , Proteínas Recombinantes/metabolismo
8.
Cell Metab ; 20(6): 979-90, 2014 Dec 02.
Artículo en Inglés | MEDLINE | ID: mdl-25470546

RESUMEN

The human growth hormone (hGH) minigene is frequently used in the derivation of transgenic mouse lines to enhance transgene expression. Although this minigene is present in the transgenes as a secondcistron, and thus not thought to be expressed, we found that three commonly used lines, Pdx1-Cre(Late), RIP-Cre, and MIP-GFP, each expressed significant amounts of hGH in pancreatic islets. Locally secreted hGH binds to prolactin receptors on ß cells, activates STAT5 signaling, and induces pregnancy-like changes in gene expression, thereby augmenting pancreatic ß cell mass and insulin content. In addition, islets of Pdx1-Cre(Late) mice have lower GLUT2 expression and reduced glucose-induced insulin release and are protected against the ß cell toxin streptozotocin. These findings may be important when interpreting results obtained when these and other hGH minigene-containing transgenic mice are used.


Asunto(s)
Hormona de Crecimiento Humana/metabolismo , Islotes Pancreáticos/metabolismo , Islotes Pancreáticos/patología , Animales , Femenino , Hormona de Crecimiento Humana/genética , Humanos , Masculino , Ratones , Ratones Transgénicos , Receptores de Prolactina/genética , Receptores de Prolactina/metabolismo , Triptófano Hidroxilasa/genética , Triptófano Hidroxilasa/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA